Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

92 Solvay Global Annual Report 2005 2005 Consolidation Scope The Group consists of Solvay S.A. and a total of 416 subsidiaries and associated companies in 54 countries. Of these, 178 are fully consolidated and 81 are proportionately consolidated, whilst the other 157 do not meet the criteria of signifi cance. In accordance with the principle of materiality, certain companies which are not of signifi cant size have not been included in the consolidation scope. Companies are deemed not to be signifi cant when they do not exceed any of the three following thresholds in terms of their contribution to the Group’s accounts: - sales of EUR 20 million, - balance sheet total of EUR 10 million, - headcount of 150 persons. Companies that do not meet these criteria are, nevertheless, consolidated where the Group believes that they have a potential for rapid development, or where they hold shares in other companies that are consolidated under the above criteria. List of companies entering or leaving the Group and changes in consolidation methods Ch = Chemicals Ph = Pharmaceuticals Pl = Plastics - = not allocated Companies entering the Group Country Company Sector Comments BELGIUM Fournier Pharma S.A. Ph purchase of Fournier Group Solvay Pharmaceuticals S.A. Ph new company LUXEMBOURG Solvay Pharmaceuticals S.a.r.l. Ph meets the criteria for consolidation FRANCE Vivalsol S.A.S. Ph meets the criteria for consolidation BTG Pharma S.A.S. Ph purchase of Fournier Group Laboratoires Fournier S.A. Ph purchase of Fournier Group Synkem S.A.S. Ph purchase of Fournier Group Fournier Industrie et Santé S.A. Ph purchase of Fournier Group ITALY Solvay Chimica Bussi S.r.l. Ch meets the criteria for consolidation Solvay Fluor Italia S.r.l. Ch meets the criteria for consolidation Alkor Draka Italia S.r.l. Pl meets the criteria for consolidation Fournier Pharma S.p.A. Ph purchase of Fournier Group GERMANY Fournier Pharma GmbH Ph purchase of Fournier Group Solvay Organics GmbH Ch meets the criteria for consolidation Girindus AG Ch purchase of Girindus Group Solvay & CPC Barium Strontium International GmbH Ch JV Barium Strontium 75% SPAIN Solvay Participaciones S.A. - meets the criteria for consolidation Laboratorios Fournier S.A. Ph purchase of Fournier Group SWITZERLAND Girindus S.A. Ch purchase of Girindus Group
PORTUGAL Fournier Farmaceutica Portugal S.A. 3S Solvay Shared Services-Sociedade de Serviços Ph purchase of Fournier Group Partilhados Unipessoal Lda - new company GREAT BRITAIN Fournier Pharmaceuticals Ltd Ph purchase of Fournier Group IRELAND Fournier Laboratories Ireland Ltd Ph purchase of Fournier Group POLAND Fournier Polska Sp. z o.o. Ph purchase of Fournier Group BULGARIA Deven AD Ch meets the criteria for consolidation SWEDEN Neopharma AB Ph new company UNITED STATES Fournier Pharma Corp, Inc. Ph purchase of Fournier Group Girindus America, Inc. Ch purchase of Girindus Group Girindus Sales Corporation Ch purchase of Girindus Group Girindus Corporation Ch purchase of Girindus Group CANADA Fournier Pharma, Inc. Ph purchase of Fournier Group MEXICO Italmex S.A. Ph meets the criteria for consolidation Solvay & CPC Barium Strontium Reynosa S. de R.L. de C.V. Ch Barium JV 75% AUSTRALIA Fournier Pharma Australia Pty Ltd Ph purchase of Fournier Group Solvay Phamaceuticals Pty Ltd Ph meets the criteria for consolidation SOUTH KOREA Solvay & CPC Barium Strontium Korea Co Ltd Ch Barium JV 75% Solvay Fluor Korea Co. Ltd Ch new company Companies leaving the Group Country Company Sector Comments BELGIUM BP Solvay Polyéthylène (Belgique) Pl sold Solvay Polyolefi ns Europe - Belgium S.A. Pl sold FRANCE Solvay Immo François 1er S.A.S - sold BP Solvay Polyéthylène (France) Société en Participation Pl sold Solvay Polyolefi ns Europe - France S.A. Pl sold ITALY Adriaplast S.p.A. Pl sold Caleppiovinil S.p.A. Pl sold BP Solvay Polyéthylène (Italie) Association en Participation Pl sold Solvay Polyolefi ns Europe - Italy S.p.A. Pl sold GERMANY Solvay Verarbeitung Holding GmbH Pl liquidated Alkor Draka Handel GmbH Pl absorbed by Alkor GmbH Kunststoffe Solvay Interox GmbH & Co KG Ch absorbed by Solvay Chemicals GmbH Solvay Interox Beteiligungs GmbH Ch absorbed by Solvay Chemicals GmbH Solvay Global Annual Report 2005 93
Page 1 and 2:
Driven by the future Growth, Compet
Page 3 and 4:
Highlights January 2005 Solvay fi n
Page 5 and 6:
Activities Group sales 2005 = EUR 8
Page 7 and 8:
Our Vision - Independent industrial
Page 9 and 10:
here to stay, in our view irreversi
Page 11 and 12:
Board of Directors and Corporate Go
Page 13 and 14:
4 Executive Committee and General M
Page 15 and 16:
Such a strategy is possible only wi
Page 17 and 18:
Specialities Solvay Specialties fro
Page 19 and 20:
Key fi gures [EUR million] Pharmace
Page 21 and 22:
Cardiometabolic Cardiovascular dise
Page 23 and 24:
Cardiometabolics Fenofi brate, TRIC
Page 25 and 26:
“ DUODOPA® entered Solvay’s pr
Page 27 and 28:
Pharmaceuticals Sector Therapeutic
Page 29 and 30:
Key fi gures [EUR million] Chemical
Page 31 and 32:
Growth To speed up its growth, the
Page 33 and 34:
Initiatives have also been launched
Page 35 and 36:
“ The ‘Soil Remediation Reagent
Page 37 and 38:
Key fi gures [EUR million] Plastics
Page 39 and 40:
Innovation “Twin-Sheet Blow Mould
Page 41 and 42:
Plastics 37 Solvay Global Annual Re
Page 43 and 44:
which it was able to take advantage
Page 45 and 46: New Business Development Priority t
Page 47 and 48: Meeting The Science Days organized
Page 49 and 50: Human Resources The Group’s fi ve
Page 51 and 52: “ At the end of this seminar, all
Page 53 and 54: Sustainable Development 2005 saw th
Page 55 and 56: Accident frequency rate Persons wor
Page 57 and 58: Management Report New records for S
Page 59 and 60: Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72: (2) Financial data by region These
Page 73 and 74: and the estimated fi nancial conseq
Page 75 and 76: The deferred taxes recorded in the
Page 77 and 78: 2005 Millions EUR Acquisitions Disp
Page 79 and 80: Neopharma On January 19, 2005 the S
Page 81 and 82: (around 300 persons) with a view to
Page 83 and 84: In 2005 the impairment tests on goo
Page 85 and 86: Solvay Group purchased 100% of the
Page 87 and 88: Post-employment benefi t plans are
Page 89 and 90: Actuarial assumptions used in deter
Page 91 and 92: Analysis of total fi nancial debt b
Page 93 and 94: In this way, at the end of 2005, th
Page 95: The following amounts relating to J
Page 99 and 100: List of fully consolidated Group co
Page 101 and 102: Solvay Salz Holding GmbH, Hannover
Page 103 and 104: CANADA Fournier Pharma, Inc., Montr
Page 105 and 106: GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108: Summary fi nancial statements of So
Page 109 and 110: Statutory auditor’s report to the
Page 111 and 112: The Solvay share compared with the
Page 113 and 114: Contacts: The Investor Relations Te
Page 115 and 116: Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

Create successful ePaper yourself

Delete template?

Save as template?